DALRD3 and breast carcinoma: Moreover, we assessed the expression levels of the two different alternative splicing variants of DALRD3 and confirmed that the two variants are both transcribed and their expression levels are higher in the ERα positive than ERα negative breast cancer cells (Figure S3B).